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ScienceDirectAging is the prime risk factor for the broad-based development of
diseases. Frailty is a phenotypical hallmark of aging and is often
used to assess whether the predicted benefits of a therapy
outweigh the risks for older patients. Senescent cells form as a
consequence of unresolved molecular damage and persistently
secrete molecules that can impair tissue function. Recent
evidence shows senescent cells can chronically interfere with
stem cell function and drive aging of the musculoskeletal system.
In addition, targeted apoptosis of senescent cells can restore
tissue homeostasis in aged animals. Thus, targeting cellular
senescence provides new therapeutic opportunities for the
intervention of frailty-associated pathologies and could have
pleiotropic health benefits.
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Loss of cell-intrinsic and cell-extrinsic
integrity perturbs musculoskeletal
rejuvenation during aging
Aged individuals can deteriorate exceptionally fast after
the onset of complications affecting the musculoskeletal
system. Tissue erosion due to life-long mechanical and
biological stress can ultimately result in pathologies suchwww.sciencedirect.com as osteoporosis, sarcopenia, and osteoarthritis, and con-
tribute to frailty [1]. While not all elderly people develop
the same age-related diseases, virtually everyone will
experience musculoskeletal complications sooner or later.
To extend, and possibly even restore, healthy life expec-
tancy in old age, it is essential to understand the cellular
changes underlying musculoskeletal decline. Tissue
regeneration by stem-cell differentiation is critical in
overcoming the relentless day-by-day damage to the
musculoskeletal system. In young tissues, differentiation
proceeds without much hindrance unless one exercises
excessively or suffers undue levels of stress. However,
during aging, the number and function of adult stem cells
declines [2,3]. For example, Pax7-expressing satellite
stem cells, can replace damaged muscle fibers [4].
Removing Pax7-positive cells from mice impairs muscle
regeneration after injury [5], whereas increased availabil-
ity of these cells enhances muscle repair [6].
In addition to cell-intrinsic regulation, muscle stem cell
regenerative capacity also depends intimately on the
microenvironment. During aging, the levels of inflamma-
tion chronically increase, an affect known as inflamma-
ging [7]. Evidence for this is provided by studies showing
that muscle stem cells (satellite cells) from aged mice
become more fibrogenic, a conversion mediated by factors
from the aged systemic environment [8]. In contrast, frailty
is reduced by the JAK/STAT inhibitor Ruxolitinib, which
reduces inflammation in naturally aged mice [9]. Stem-cell
impairing cues do not necessarily have to come from local
sources but can travel over a distance. Heterochronic para-
biosis experiments showed that transfusion of old blood
impairs stem cell function in young recipient mice [10],
while the transfer of young blood factors restoring muscle
regeneration and muscle stem-cell activation in aged ani-
mals [11]. Therefore, there is a great interest in developing
methods to interfere with the age-associated pro-inflam-
matory signaling profile. The question is how? To address
this question, cellular senescence has recently gained
attention as a potential candidate for intervention.
Signaling noise by senescent cells impedes
tissue homeostasis during aging
As we age, each cell in our body accumulates damage.
Earlier in life, this damage is usually faithfully repaired
[12], but over time more and more damage gets left
behind. This can trigger a molecular chain of events,
resulting in chromatin remodeling and the entry of cellsCurrent Opinion in Pharmacology 2018, 40:147–155
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cycle arrest, called cellular senescence. Senescence can
be invoked in healthy cells that experience a chronic
damage response, either involving direct DNA damage or
events that mimic the molecular response, such as telo-
mere shortening or oncogenic mutations [13]. As a con-
sequence, these cells undergo an irreversible cell cycle
arrest, effectively limiting the damage. So far, so good,
except that senescent cells secrete a broad range of
growth factors, pro-inflammatory proteins, and matrix
proteinases that alter the microenvironment: The Senes-
cence-Associated Secretory Phenotype (SASP) [14].
Senescent cells persist for prolonged periods of time and
eventually accumulate during aging [15]. This also means
there is a gradual and, importantly, ever-present build-up
of deleterious molecules. Thus, senescence can have
continuous detrimental effects on tissue homeostasis
during aging. That senescent cells are a direct cause of
aging was proven beyond a doubt in studies in which
senescent cells were genetically or pharmacologically
removed. In these studies, both rapidly and naturally
aged mice maintained healthspan for much longer, or
even showed signs of aging reversal [16,17,18,19]. Fac-
tors secreted by senescent cells can induce pluripotency
in vivo [20]. As such, these can impair normal stem cell
function by forcing a constant state of reprogramming,
something we dubbed a ‘senescence — stem lock’ [13].
This is supported by observations that factors secreted by
senescent cells induce pluripotency in vivo [20]. Age-
associated inflammation may thus deregulate normal
stem cell function at different levels, for instance by
preventing stem cells from producing differentiated
daughter cells. Due to the constant secretion of SASP
factors, senescent cells could thus impair local and distant
stem cell function and differentiation in times of need.
Here, we will highlight the interplay between senes-
cence, the SASP and stemness in the individual muscu-
loskeletal compartments: muscle, bone and cartilage.
Skeletal muscle: an intrinsic interplay between
senescence and stemness
Several reports link senescence to muscle aging and
muscle stem cell dysfunction. For example, expression
of the major senescence marker p16INK4A prevents tissue
regeneration by satellite cells after damage [21]. Fast-
aging BubR1H/H mice develop sarcopenia, and after
genetic removal of senescent cells, they showed a reduc-
tion in kyphosis and an increase in muscle fiber diameter,
findings suggestive of reduced sarcopenia [16]. Likewise,
senescence of muscle stem cells occurs in muscles of mice
with distinct dystrophinopathies, such as Duchenne mus-
cular dystrophy or Steinert’s diseases [22–25].
The skeletal muscle stem cell niche is a candidate through
which senescent cells may exert their deleterious effects.
Interleukin 6 (IL-6) is a pleiotropic cytokine that can beCurrent Opinion in Pharmacology 2018, 40:147–155 released by inflammatory cells and by muscle fibers (acting
as a myokine). IL6 is also a major component of the SASP
[14], and has been shown to regulate the transition of
satellite cells from a quiescent to an activated state [26].
This is beneficial upon acute tissue stress, where IL-6 is
transiently released by growing myofibers to activate satel-
lite cells and thereby stimulate myogenesis [26]. However,
the chronic IL-6 signaling caused by senescence during
aging would have very detrimental effects on muscle
function. Indeed, muscle atrophy is linked to high IL-6
levels in patients with inflammatory diseases such as cancer
[27]. In addition, persistent IL-6 expression was shown to
increase muscle degradation in combination with other
circulating factors in mice [28,29]. Interestingly, when
IL-6 receptors were blocked in mice with ectopic IL-6
expression, atrophy could be attenuated, indicating a direct
regulation of muscle wasting by IL-6 [30]. Chronic IL-6
signaling causes protein degradation in muscle, explaining
age-related muscle wasting [31]. Additionally, IL-6 depen-
dent muscle degradation may be linked to stem cell func-
tion. For example, senescence induction after muscle
injury canpromote Pax7 positive unipotent cells to undergo
reprogramming and regain pluripotency [32]. This pro-
cess is dependent on IL-6 secreted by the senescent cells.
Further underscoring the role between the senescent niche
and stemness in the muscle is provided by elegant work
employing a system in which the four Yamanaka stem cell
factors, Oct4, Sox2, Klf4 and c-Myc (OSKM) were tran-
siently expressed in vivo. This resulted in a marked reduc-
tion in senescence, SASP factors as IL6 and improved
recovery in muscle injury experiments [33]. Together,
this supports a model we postulated previously that
because senescence increases locally during aging hotspots
are formed of high IL6 concentrations. This can cause
neighboring cells to become pluripotent. However, due
to the chronic nature of the SASP, senescent cells provide a
continuous source of IL6 causing these cells remain per-
manently locked in a pluripotent state and rendering them
unable to rejuvenate the tissue after injury [13] (Figure 1).
Although satellite dysfunction has been linked to sarco-
penia, this relationship is controversial. Recent studies
suggest that the decline in satellite cell function during
aging is not the cause of sarcopenia [34,35]. When satellite
cells were genetically removed over a prolonged period,
no difference in muscle mass was observed compared
with mice that maintained their satellite cells. However,
there was a clear increase in fibrosis, indicating that
satellite cells are indeed crucial for muscle homeostasis.
Furthermore, several studies show that sarcopenic muscle
has a reduced ability to recover after injury, which is
dependent on satellite cell function [5,21,35,36]. Over-
all, while the role of satellite cells in sarcopenia is still
debated, there is consensus that Pax7 positive cells are
required for regeneration after muscle injury and that
reduced function of these stem cells leads to age-related
frailty.www.sciencedirect.com
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Aged muscle fibers show atrophy that is linked to an age-related increase in cellular senescence. Satellite cells lose proliferation capacity through
senescence induction or the chronic presence of SASP factors such as IL-6. Thus, regeneration of damaged tissue is prevented. Additionally, IL-
15 secreted by muscle tissue facilitates NK cell survival in young organisms, while IL-6 represses these immune cells during aging and thereby
reduces the natural ablation of senescent cells, aggravating loss of muscle mass observed during aging.The myokines released by muscle cells not only signal to
stem cells, but also attract immune cells that can facilitate
tissue repair and regulate immune cell function. IL-15 is
released by muscle cells in response to exercise and
promotes survival of NK cells [37,38]; in contrast, NK
cells are inhibited by IL-6 and TNFa [39]. An age-related
decrease in muscle mass could therefore lead to a
decrease in IL-15 and thereby a decrease in the number
of NK cells, an effect aggravated by an increase in
systemic IL-6 levels (Reviewed in [40]). Importantly,
NK cells are natural eliminators of senescent cells [41].
Muscle atrophy during aging thus adds to the build-up of
senescence by reducing the ability of the immune system
to clear senescent cells. This, in turn, further accelerates
muscle loss and age-related frailty. Studies are underway
to determine whether anti-senescence treatment can
overcome muscle loss. Aging is the greatest risk factor
for most chronic diseases, and mechanistic links between
aging and disease are starting to emerge. Several studies
show an involvement of cellular senescence, and in
particular, muscle stem cell senescence, in distinct types
of muscular dystrophies. In Myotonic dystrophy type 1
(DM1 or Steinert’s disease), entry into senescence ofwww.sciencedirect.com human satellite cell-derived myoblasts correlates with a
lower proliferative rate than age-matched controls and has
been causally implicated in the progressive atrophy and
degeneration of DM1 muscles [22,23]. Similarly, cellular
senescence traits have been described in mdx mice, a
widely used model of Duchenne muscular dystrophy
(DMD), correlating with poor regenerative capacity
[24,25,42]. Premature cellular senescence also underlies
myopathy in a mouse model of limb-girdle muscular
dystrophy [43]. Whether interference in cellular senes-
cence can provide a therapeutic approach for these mus-
cle diseases is unknown.
Bone: senescence distorts the balance
between resorption and formation
During aging, there is an increase in senescence in the
bone. This, in turn, can lead to changes in bone density.
Bone consists of multiple cell types, including osteoblasts
that form bone, osteoclasts that break down bone tissue,
and osteocytes that make up the majority of bone cells
(reviewed in [44]). Out of the various cell types that are
affected, the main SASP producing cells are senescent
osteocytes [45]. Osteocytes are known to influenceCurrent Opinion in Pharmacology 2018, 40:147–155
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In aged bone, the balance between bone formation by osteoblasts
and bone resorption by osteoclasts is distorted. An accumulation of
senescent cells is observed that promote an increased osteoclast
activation through the SASP. Bone loss is also worsened by the
inhibition of osteoblast formation by pro-inflammatory factors. For
example, known SASP factors cause mesenchymal stem cells to favor
adipogenesis over osteoblast production.osteoblast and osteoclast function [46], and SASP factors
secreted by osteocytes, such as IL-1 and MMP13,
increase osteoclast differentiation and thereby increase
bone resorption to cause the age-related bone loss associ-
ated with osteoporosis [47–49]. The conditioned medium
of senescent cells can decrease osteoblast function in vitro
and promote osteoclast activity [50]. Furthermore, inhi-
bition of senescence induction stimulates osteogenesis
and prevents osteoporosis [51]. These observations indi-
cate a causal role of senescence in disrupting the balance
between bone formation and resorption, leading to oste-
oporosis (Figure 2).
Bone stem cell function during aging is likely influenced
by secreted SASP factors. Osteoblasts have a relatively
short lifespan and are derived from mesenchymal stem
cells in the bone marrow (BMSCs), periosteum and
elsewhere [52]. BMSCs can give rise to both osteoblasts
and adipocytes [53]. This balance is heavily influenced by
the microenvironment [54], and during osteoporosis oxi-
dative stress and inflammatory cytokines influence
BMSCs to favor adipogenesis over osteogenesis [55,56].
Therefore adipose tissue accumulation is a hallmark of
osteoporosis and is linked to senescence in the microen-
vironment. Furthermore, BMSCs show a reduced differ-
entiation capacity during aging. For example, serum from
aged individuals inhibits differentiation of BMSCs into
osteoblasts [57]. Additionally, BMSCs can becomeCurrent Opinion in Pharmacology 2018, 40:147–155 senescent during aging, secreting SASP proteins and
promoting osteoclast activity [58,59]. Overall, these
observations indicate that targeting senescent cells in
bone would likely improve bone stem cell function.
There are several mouse models that show accelerated
aging and are known to have an increased number of
senescent cells, such as mice with DNA repair or telome-
rase deficiency; such mice often show osteoporosis and
other musculoskeletal afflictions [60,61]. They are there-
fore ideal model organisms for studying the effect of
senescence in these disorders. For example, Klotho-defi-
cient mice show accelerated senescence and a wide
variety of age-related diseases, including osteoporosis.
When these mice were crossed with p16ink4a knockout
mice, osteoporosis was attenuated [61], indicating that
senescent cell ablation can potentially prevent this dete-
rioration. Indeed, osteoporosis was delayed in naturally
aged INK-ATTAC mice when senescent cells, which
continuously develop, were ablated twice a week. More-
over, these mice had an improved microarchitecture and
strength [62]. The reduction of senescent cells likely
leads to a lower level of inflammation in the bone. This
then reduces the formation of osteoclasts and prevents
bone degradation. Indeed, in INK-ATTAC mice, bone
resorption was lowered and bone formation improved. In
conclusion, senescent cell removal prevents age-related
bone loss in mice.
Cartilage: senescence-associated chronic
inflammation perturbs cartilage regeneration
Articular cartilage — a flexible connective tissue that
protects the ends of bones within a joint — affords smooth
surfaces with low friction for movement, and facilitates
transmission of loads to the underlying bone. This tissue
mainly consists of extracellular matrix produced by chon-
drocytes, the cell type present in cartilage. The regenera-
tive potential of cartilage after damage is limited, possibly
because the tissue contains a low number of mesenchy-
mal stem cells [63]. Furthermore, like muscle stem cells,
these stem cells are less able to regenerate damaged
tissue with age. This is in part due to intrinsic MSC
aging and senescence induction [64,65], but is also due to
the altered tissue microenvironment and chronic inflam-
mation [66]. Additionally, chondrocytes can express stem-
ness markers in osteoarthritis [67,68]. Again, inflamma-
tory factors promote a chronic dedifferentiated state and
thereby prevent tissue repair during aging [69]. Alto-
gether, this leads to thinning of cartilage during aging,
resulting in stiffness and pain in the joints that are
characteristic of osteoarthritis [70] (Figure 3).
A causal role of senescence in osteoarthritis was shown by
transplanting senescent cells into mouse joints, resulting
in pain and morphological changes indicative of osteoar-
thritis [71].www.sciencedirect.com
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Age-related cartilage degeneration leads to osteoarthritis. Senescent chondrocytes present in aged cartilage cannot proliferate to regenerate
damaged cartilage and induce extracellular matrix degeneration through the SASP. Furthermore, cartilage regeneration is inhibited during aging
due to senescent mesenchymal stem cells.Furthermore, chondrocytes show an age-related increase
in senescence, and during osteoarthritis pro-inflammatory
cytokines such as the prominent SASP factor IL-1 induce
excess expression of matrix metalloproteinases (MMPs),
leading to cartilage loss [72]. Increased levels of circulat-
ing SASP factors such as IL-6 are linked to frailty and risk
of osteoarthritis [73]. Additionally, in a mouse model of
osteoarthritis, overexpression of SIRT6 prevents senes-
cence induction and concurrent inflammation, thereby
reducing cartilage degeneration [74]. This finding indi-
cates that eliminating senescent cells from cartilage
would attenuate osteoarthritis and improve joint function,
especially since chondrocyte death does not seem to drive
cartilage damage in response to injury [75]. Several stud-
ies have examined the effect of senescent cell removal on
osteoarthritis development. For example, osteoarthritis
was surgically induced in mice through anterior cruciate
ligament transection (ACLT) in the knee joint. In this
model, genetic removal of senescent cells delayed the
development of osteoarthritis, evidenced by reduced
inflammation in the knee joint and an increase in cartilage
development, indicating better joint function [76]. The
mice had less pain after the senescent cells were removed.
Furthermore, osteoarthritis occurs naturally in aged INK-
ATTAC mice, and cartilage degeneration was attenuated
after removal of senescent cells in this model.
Targeting senescence to counteract age-
related frailty
The encouraging results obtained upon genetic elimina-
tion of senescent cells have important implications for thewww.sciencedirect.com treatment of musculoskeletal deterioration. Since senes-
cence is thought to play a significant role in the progres-
sion of age-related frailty, anti-senescence drugs can be
predicted to benefit patients with musculoskeletal dis-
orders (Table 1).
Currently, drugs that target inflammatory cytokines are
tested in patients with musculoskeletal diseases. For
example, several strategies for IL1 inhibition in osteoar-
thritis have been explored. These therapies include IL1
receptor antagonist proteins (IRAP), monoclonal antibo-
dies targeting free IL1 or the IL1-receptor, and an inhib-
itor of IL1b production called Diacerein (reviewed in
[77]). Most of these therapies show a trend of pain
reduction versus placebo. However, these results were
often not statistically significant, possibly due to the short
half-life of the antagonist proteins or blocking antibodies.
Only Diacerein treatment has shown significant anti-
inflammatory effects and pain reduction in most studies
[77]. Treatment of mdx dystrophic mice with the NAD+
precursor nicotinamide riboside (NR) prevented senes-
cence of muscle stem cells, and this rejuvenated their
regenerative capacity [24]. The Notch pathway is chroni-
cally activated in severely dystrophic muscles of mdx
mice double mutant for dystrophin and utrophin, and
blocking this pathway with the g-Secretase inhibitor
DAPT reduced stem cell senescence and the histopath-
ological features of DMD [42]. Importantly, abolition of
p16INK4a, which accumulates abnormally in satellite cells
of DM1 muscles, partially restores early growth arrest and
reduces senescence in vitro [22], reinforcing the idea thatCurrent Opinion in Pharmacology 2018, 40:147–155
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Table 1
Effects of senescent cell removal on the musculoskeletal system
Tissue Model system Senescence cleared/delayed by: Improvements musculoskeletal system Ref.
Fast aging BubR1H/H mice
Naturally aged mice
Fast aging LAKI (LmnaG609G)
INK-ATTAC
Navitoclax
Transient OSKM expression
Kyphosis reduction, increase in muscle
fiber diameter
Improved muscle stem cell function
Improved regeneration after muscle injury
[16]
[78]
[33]
Klotho deficient mice
Naturally aged mice
p16INK4A Knockout
INK-ATTAC
Delay in osteoporosis
Improved bone structure and strength,
improved bone formation, reduction in bone
resorption
[61]
[62]
ACLT in the mouse Knee joint
Naturally aged mice
Fast aging XpdTTD/TTD mice
p16::3MR
INK-ATTAC
FOXO4-p53 interfering peptide
Reduced inflammation, pain reduction,
increase in cartilage development
Reduced cartilage degeneration
Improved running wheel performance
[76]
[62]
[19]this mechanism might participate in the impaired regen-
eration of DM1 muscles. Notably, the regenerative deficit
of satellite cells from dystrophic muscles resembles that
of geriatric mice, which also show p16INK4a-induced
senescence and can be rejuvenated by silencing of the
gene encoding p16INK4a [21]. Overall, these studies
show limited effects, and the long-term safety of these
drugs and/or genetic approaches has yet to be assessed.
However, it is unlikely that essential molecules and
pathways such as Notch or p16INK4a can be targeted
systemically without severe secondary effects. In addi-
tion, these strategies are aimed at reducing symptoms and
do not treat the underlying causes of disease progression.
Removal of senescent cells is expected to reduce these
inflammatory proteins while preserving stem cell function
and is therefore expected to be safer and have more long-
lasting effects.
The results obtained after genetic removal of senescent
cells prompted a search for therapeutically applicable
anti-senescence compounds. A small number of these
compounds have been discovered, with varying degrees
of success. One example is Navitoclax, a BCL2 family
inhibitor. In the musculoskeletal system, Navitoclax was
found to decrease the expression of cytokines that pro-
mote osteoclast activity in vitro, such as IL-1a and MMP-
13 [58]. Furthermore, muscle stem cells isolated from
naturally aged, Navitoclax-treated mice showed
improved clonogenicity [78].
A major challenge when developing anti-senescence
therapies is to avoid toxicity to healthy non-senescent
cells. It is therefore important to identify the unique
characteristics of senescent cells that can be targeted
by a therapeutic compound. Senescent cells often express
persistent nuclear damage foci called DNA-SCARS
(DNA Segments with Chromatin Alterations Reinforcing
Senescence) that contain DDR proteins such as 53BP1,
gH2AX and activated p53 [79]. These DNA-SCARS play
a role in maintaining permanent growth arrest and are
critical for SASP expression. In addition, we recentlyCurrent Opinion in Pharmacology 2018, 40:147–155 showed that the transcription factor FOXO4 resides
within PML bodies fused to these persistent damage foci
[19]. Here, FOXO4 binds p53 and prevents p53-depen-
dent apoptosis. In order to disrupt this interaction and to
induce apoptosis, we prospectively generated a D-Retro-
Inverso peptide mimicking the FOXO4 p53-binding
domain. This peptide, FOXO4-DRI, causes the release
of p53 to the cytoplasm, where p53 indeed induces
apoptosis in a transcription independent manner. Indeed,
in vivo use of FOXO4-DRI shows promising results. For
these experiments we made use of XpdTTD/TTD mice that
show accelerated aging and age-related ailments such as
osteoporosis and are therefore an ideal model for muscu-
loskeletal diseases [60]. FOXO4-DRI treatment
improved overall fitness and renal function in these mice,
including an improved running wheel performance [19],
an especially promising result for the treatment of mus-
culoskeletal diseases. FOXO4-DRI showed around
10 fold selectivity for eliminating senescent vs. control
cells. While enough for experiments in rodents, transla-
tion to the clinic requires further improvement to elimi-
nate toxicity, which would be intolerable in this setting.
Such efforts are now underway in our laboratory.
Unanswered questions
As we highlighted here, the tissues of the musculoskeletal
system are damaged by inflammation during aging. Cel-
lular senescence, by driving a persistent inflammatory
response, is a major contributor to these effects. However,
it remains unclear which senescent cell types are the main
producers of these pro-inflammatory factors. Aging of the
musculoskeletal system is due to both local and systemic
factors. For example, senescent cells transplanted into
cartilage can independently cause osteoarthritis [71]. On
the other hand, systemically increased IL-6 levels are
linked to muscle wasting, and the immune system also
seems to be crucial in this process [28,29]. This systemic
inflammation can be caused by many cell types. For
example, adipose tissue significantly contributes to sys-
temic inflammation [80]. Fat present in joints can produce
factors that promote osteoarthritis [81]. In turn, cells ofwww.sciencedirect.com
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and influence overall tissue integrity. For example, mus-
cle cells affect NK cells during aging and, as NK cells are
responsible for clearance of senescent cells [41], these
would also influence the systemic senescence burden.
Since various anti-senescence compounds potentially kill
distinct subsets of senescent cells, it is vital to know which
cell type to target; knowledge about which senescent cells
contribute most to musculoskeletal degeneration will
ultimately guide the development of effective treatment.
Anti-senescence therapy may also be beneficial for sev-
eral incurable muscular dystrophies and for wasting, by
reducing inflammaging and hence boosting the satellite
cell regenerative functions. Interestingly, cellular senes-
cence has been shown to mediate fibrotic pulmonary
disease, and senescent cell ablation improves pulmonary
function in this setting [82]. Most dystrophinopathies also
feature increased muscle fibrosis [83], which aggravates
disease progression by substituting muscle with scar
tissue, and it is plausible that anti-senescence cocktails
will also halt fibrosis and improve patient health status.
Thus, elimination of senescent cells may have benefits for
tissue repair by reversing several detrimental processes;
however, it remains to be determined whether senes-
cence should be blocked partially or totally or eliminated
only once early potential stemness-related functions have
been completed. The answers to these questions may not
be easy to obtain, yet we are rapidly obtaining tools that
allow manipulation of the senescence process (for remov-
ing senescent cells, neutralizing the SASP, or both pro-
cesses). The final goal is to preserve stem cell benefits
while minimizing the deleterious consequences of
senescence.
It also remains unclear how tissues rejuvenate after senes-
cent cell ablation and whether side effects or unexpected
challenges will occur. For example, in addition to its
potential to eliminate senescent cells, tissue engineering
is being explored as a treatment for musculoskeletal
diseases. In this scenario, stem cells are isolated and
healthy tissue is generated ex vivo to replace damaged
tissues such as cartilage and bone. For example, mesen-
chymal stem cells can be isolated and cultured on a
biodegradable scaffold where they are stimulated with
TGFb to induce differentiation into chondrocytes [84].
This newly formed cartilage could then be used for
surgical reconstruction of joints. However, a major chal-
lenge in tissue engineering is to prevent stem cell senes-
cence [85]. It remains unclear whether similar issues will
arise after senescence clearance. So far, tissue regenera-
tion seems efficient after these cells are removed. For
example, although cartilage has a weak regenerative
potential, it is rejuvenated after senescent cells are
removed. Tissue-specific stem cells are likely key to this
regeneration. It is possible that the reduction of SASP
proteins in the tissue microenvironment releases these
cells from their ‘stem cell lock’, resulting in a restoredwww.sciencedirect.com regenerative potential. In addition, cells that are dedif-
ferentiated due to senescence, such as chondrocytes,
could help rejuvenate musculoskeletal tissue. In general,
multiple factors likely contribute to this rejuvenation.
Both local and systemic inflammation are expected to
decline, affecting immune system functioning, natural
senescent cell clearance, stem cell function, and tissue
regeneration.
In conclusion, targeting senescence has the potential to
prevent or reverse multiple age-related diseases and to
reduce frailty. Furthermore, it seems likely that thera-
peutically applicable anti-senescence compounds will be
available in the future. However, the toxicity of these
drugs remains a major concern. Periodic treatments will
likely be necessary to maintain possible beneficial effects
and it is still largely unknown what the effect of multiple
treatment rounds will be. Therefore, the timing and
frequency of these treatments should be studied, as well
as the long-term effect of senescence clearance on bio-
logical processes such as stem cell function.
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